
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
U.S. House Committee Investigating Drugmakers Involved in China Drug Trials: Report
2
Uncertainty Surrounding Pharma Tariff Deadlines
3
AlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApS
4
Preparing for the July 31 Pharma Tariff Deadline
5




